Literature DB >> 6431954

Physiologic and supraphysiologic increases in lipoprotein lipids and apoproteins in late pregnancy and postpartum. Possible markers for the diagnosis of "prelipemia".

A Montes, C E Walden, R H Knopp, M Cheung, M B Chapman, J J Albers.   

Abstract

A supraphysiologic (greater than 95th percentile) rise in plasma lipids in pregnancy may serve as a marker for "prelipemia" in the same way that gestational diabetes is a marker for prediabetes. To qualify as prelipemic, subjects with an abnormal lipid rise antepartum must return to normal postpartum but may have other identifying characteristics. This paper describes the antepartum-postpartum changes of lipoprotein lipids and apoproteins at 34 to 38 weeks of gestation and 6 and 20 weeks postpartum in 23 subjects with physiologic and six subjects with supraphysiologic plasma lipid increases during pregnancy. These results are compared to measurements in 23 nonpregnant controls matched for weight, age, and race. In subjects with a physiologic antepartum lipid rise, postpartum total triglyceride and very low density lipoprotein (VLDL) lipids (cholesterol and triglyceride) and apo B returned to baseline within 6 weeks. In contrast, low density lipoprotein (LDL) showed a slow postpartum decline in lipids and apo B with elevations remaining at 20 weeks postpartum. High density lipoprotein (HDL) cholesterol concentrations, elevated in pregnancy, remained elevated at 6 weeks postpartum, but fell to baseline by 20 weeks postpartum. HDL triglyceride and apo A-l concentrations, both elevated in pregnancy, returned to baseline by 6 weeks postpartum. A supraphysiologic triglyceride rise in pregnancy was associated with a slower return of total triglycerides and VLDL to baseline, reduced HDL cholesterol ante- and postpartum, atypical changes in LDL cholesterol during pregnancy and postpartum, and evidence of hyperlipidemia among family members. Two subjects with hypercholesterolemia in the nonpregnant state showed no marked exaggeration of total or LDL cholesterol concentrations in pregnancy. The data support the hypothesis that a supraphysiologic rise in plasma triglyceride concentrations in late pregnancy may serve as a marker of prelipemia. Proof of the hypothesis requires further investigation and longer follow-up.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431954     DOI: 10.1161/01.atv.4.4.407

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  15 in total

1.  Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care.

Authors:  John L Kitzmiller; Jennifer M Block; Florence M Brown; Patrick M Catalano; Deborah L Conway; Donald R Coustan; Erica P Gunderson; William H Herman; Lisa D Hoffman; Maribeth Inturrisi; Lois B Jovanovic; Siri I Kjos; Robert H Knopp; Martin N Montoro; Edward S Ogata; Pathmaja Paramsothy; Diane M Reader; Barak M Rosenn; Alyce M Thomas; M Sue Kirkman
Journal:  Diabetes Care       Date:  2008-05       Impact factor: 19.112

Review 2.  Maternal cholesterol levels during gestation: boon or bane for the offspring?

Authors:  V S Jayalekshmi; Surya Ramachandran
Journal:  Mol Cell Biochem       Date:  2020-09-22       Impact factor: 3.396

Review 3.  Hershey Medical Center Technical Workshop Report: optimizing the design and interpretation of epidemiologic studies for assessing neurodevelopmental effects from in utero chemical exposure.

Authors:  Robert W Amler; Stanley Barone; Aysenil Belger; Cheston M Berlin; Christopher Cox; Harry Frank; Michael Goodman; Jean Harry; Stephen R Hooper; Roger Ladda; Judy S LaKind; Paul H Lipkin; Lewis P Lipsitt; Matthew N Lorber; Gary Myers; Ann M Mason; Larry L Needham; Babasaheb Sonawane; Theodore D Wachs; Janice W Yager
Journal:  Neurotoxicology       Date:  2006-07-21       Impact factor: 4.294

4.  Second trimester anti-angiogenic proteins and preeclampsia.

Authors:  Catherine L Haggerty; Michael E Seifert; Gong Tang; Jorn Olsen; Debra C Bass; S Ananth Karumanchi; Roberta B Ness
Journal:  Pregnancy Hypertens       Date:  2012-04-01       Impact factor: 2.899

5.  Dietary fat impacts fetal growth and metabolism: uptake of chylomicron remnant core lipids by the placenta.

Authors:  Sandra L Rebholz; Katie T Burke; Qing Yang; Patrick Tso; Laura A Woollett
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-17       Impact factor: 4.310

6.  In utero exposure to di(2-ethylhexyl)phthalate suppresses blood glucose and leptin levels in the offspring of wild-type mice.

Authors:  Yumi Hayashi; Yuki Ito; Hisao Naito; Hazuki Tamada; Nozomi Yamagishi; Takaaki Kondo; Tetsuya Ishikawa; Frank J Gonzalez; Tamie Nakajima
Journal:  Toxicology       Date:  2019-01-17       Impact factor: 4.221

Review 7.  Fetoplacental vascular endothelial dysfunction as an early phenomenon in the programming of human adult diseases in subjects born from gestational diabetes mellitus or obesity in pregnancy.

Authors:  Andrea Leiva; Fabián Pardo; Marco A Ramírez; Marcelo Farías; Paola Casanello; Luis Sobrevia
Journal:  Exp Diabetes Res       Date:  2011-11-24

8.  Serum concentrations of selected persistent organic pollutants in a sample of pregnant females and changes in their concentrations during gestation.

Authors:  Richard Y Wang; Ram B Jain; Amy F Wolkin; Carol H Rubin; Larry L Needham
Journal:  Environ Health Perspect       Date:  2009-03-12       Impact factor: 9.031

Review 9.  Excessive early-life cholesterol exposure may have later-life consequences for nonalcoholic fatty liver disease.

Authors:  Jerad H Dumolt; Mulchand S Patel; Todd C Rideout
Journal:  J Dev Orig Health Dis       Date:  2020-04-15       Impact factor: 2.401

10.  Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection.

Authors:  Samuel R Schnittman; Helen Byakwaga; Yap Boum; Jerome Kabakyenga; Lynn T Matthews; Tricia H Burdo; Yong Huang; Russell P Tracy; Jessica E Haberer; Annet Kembabazi; Angela Kaida; Daniela Moisi; Michael M Lederman; David R Bangsberg; Jeffrey N Martin; Peter W Hunt
Journal:  Open Forum Infect Dis       Date:  2021-05-17       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.